Shows that neoadjuvant chemotherapy increases the risk of implant loss in women undergoing breast reconstruction, suggesting a need for careful patient evaluation.
In this study, neoadjuvant chemotherapy is an independent risk factor for TE loss after immediate tissue expander-based breast reconstruction. Further analysis of adjuncts, implant factors, and specific chemotherapeutic agents is needed.
No takes yet. Share an insight, caveat, or question.
DeVito et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: